{"id":"patiromer-oral-product","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypomagnesemia"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal discomfort"}]},"_chembl":{"chemblId":"CHEMBL2107840","moleculeType":"Small molecule"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Patiromer is a cation exchange polymer that binds potassium ions in the colon through ionic interactions, preventing potassium reabsorption and increasing fecal potassium excretion. This mechanism allows for reduction of hyperkalemia without systemic absorption, making it suitable for chronic management of elevated serum potassium levels in patients taking medications that increase potassium retention.","oneSentence":"Patiromer is a non-absorbed potassium binder that sequesters potassium in the gastrointestinal tract to reduce serum potassium levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:59:55.290Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperkalemia in patients with chronic kidney disease or heart failure on renin-angiotensin-aldosterone system inhibitors"}]},"trialDetails":[{"nctId":"NCT06858280","phase":"PHASE3","title":"Patiromer and Diet/hrQoL in Chronic Dialysis","status":"RECRUITING","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2025-07-08","conditions":"Hyperkalaemia, Chronic Kidney Disease Stage 3 and 4, Dietary Intervention","enrollment":40},{"nctId":"NCT04585542","phase":"PHASE4","title":"Comparison of Potassium Binders in the ER","status":"TERMINATED","sponsor":"University of California, Irvine","startDate":"2020-10-20","conditions":"Acute Hyperkalemia, Oral Potassium Binders","enrollment":37},{"nctId":"NCT03781089","phase":"PHASE4","title":"Patiromer Efficacy to Reduce Episodic Hyperkalemia in End Stage Renal Disease Patients","status":"COMPLETED","sponsor":"Duke University","startDate":"2019-06-20","conditions":"Hyperkalemia, End Stage Renal Disease","enrollment":36},{"nctId":"NCT05786469","phase":"PHASE3","title":"Patiromer Trial in CKD Stage IIIB to V","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2023-08-02","conditions":"Hyperkalemia","enrollment":2},{"nctId":"NCT04443608","phase":"PHASE4","title":"Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management","status":"TERMINATED","sponsor":"Comprehensive Research Associates","startDate":"2020-10-08","conditions":"Hyperkalemia","enrollment":115},{"nctId":"NCT03740048","phase":"PHASE3","title":"A Pilot Trial of Twice-weekly Versus Thrice-weekly Hemodialysis in Patients With Incident End-stage Kidney Disease","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2019-06-19","conditions":"End Stage Renal Failure on Dialysis","enrollment":51},{"nctId":"NCT05029310","phase":"PHASE4","title":"Effects of Patiromer on Pharmacokinetics of Immunosuppresive Drugs in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2021-09-01","conditions":"Hyperkalemia, Kidney Transplant","enrollment":13}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Valtressa"],"phase":"marketed","status":"active","brandName":"Patiromer Oral Product","genericName":"Patiromer Oral Product","companyName":"Wake Forest University Health Sciences","companyId":"wake-forest-university-health-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Patiromer is a non-absorbed potassium binder that exchanges sodium for potassium in the gastrointestinal tract, reducing serum potassium levels. Used for Hyperkalemia (elevated serum potassium levels).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}